Kwan et al. conducted a study in which a small molecular inhibitor called TAK-242 was used to inhibit TLR4 and reduce the development of HCC and the progression of small preexisting adenomas in a HepPten- mouse model of NASH-associated HCC. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatohepatitis.